Windward Bio Group AG (WWB)
| Market Cap | 1.39B |
| Revenue (ttm) | n/a |
| Net Income | -68.21M |
| EPS | -8.85 |
| Shares Out | 58.04M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 166,320 |
| Open | 22.01 |
| Previous Close | 22.64 |
| Day's Range | 21.12 - 25.00 |
| 52-Week Range | 18.35 - 33.99 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Dec 5, 2026 |
About WWB
Windward Bio Group AG operates as a clinical stage biotechnology company that develops ultra-long-acting antibody medicines for patients with respiratory and dermatologic diseases. Its drug candidates WIN378, an ultra-long-acting and novel fully human monoclonal antibody, which has completed Phase I clinical study that inhibits thymic stromal lymphopoietin (TSLP); and WIN027, an ultra-long-acting bispecific antibody that is in Phase I clinical study simultaneously targets TSLP and interleukin-13 (IL-13) and two clinically validated drivers of i... [Read more]
Financial Performance
Financial StatementsNews
Windward Bio Group AG Transcript: Jefferies Global Healthcare Conference
WIN378 has advanced to phase III asthma testing, with phase II COPD dose-ranging ongoing and twice-yearly dosing as a key differentiator. WIN027 combines TSLP and IL-13 targeting, with global COPD and atopic dermatitis studies planned.
Windward Bio to Participate at the Jefferies London Global Healthcare Conference
BASEL, Switzerland, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Windward Bio Group AG ("Windward") (Nasdaq: WWB), a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patie...
Windward Bio Announces Closing of $251.2 Million Initial Public Offering and Concurrent Private Placement, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
BASEL, Switzerland, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Windward Bio Group AG ("Windward") (Nasdaq: WWB), a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patie...
Windward Bio closes first day of trading with $1.69B market capitalization
Windward Bio Group (WWB) began trading on the Nasdaq Global Select Market on Nov. 13, 2026. The company priced its initial public offering at $17.00 per share and sold approximately…
Innovative Immunology Biotech Windward Bio Lists on Nasdaq
SHANGHAI, Nov. 14, 2026 /PRNewswire/ -- Windward Bio, a portfolio company of Qiming Venture Partners and a clinical-stage biotechnology company, successfully listed on Nasdaq on November 13, 2026. Win...
Windward Bio Announces Pricing of Initial Public Offering
BASEL, Switzerland, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Windward Bio Group AG (“Windward”) (Nasdaq: WWB), a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patie...
Windward Bio Group AG Registration statement: Registration filing
Windward Bio Group AG filed a registration statement on November 9, 2026, providing details about a securities offering with the SEC.
Windward Bio Group AG Registration statement: Registration filing
Windward Bio Group AG filed a registration statement on October 30, 2026, providing details about a securities offering with the SEC.
Windward Bio Group AG IPO Registration Document (F-1)
Windward Bio Group AG has filed to go public with an IPO on the NASDAQ
Windward Bio Group AG Registration statement: Registration filing
Windward Bio Group AG filed a registration statement on October 23, 2026, providing details about a securities offering with the SEC.